Skip to content
← Lobby register
EF
Trade & Business

European Federation of Pharmaceutical Industries and Associations

🇪🇺 LUXEMBOURGRegistered 04/034 staff
Disclosed budget
€6,000,000 — €6,499,999
Meetings 12mo
106
Policy files
12
Accredited passes
15

Recent meetings

DateCommissioner / CabinetTopicFile
26 Mar 2026
Nils Behrndt (Deputy Secretary-General)
Commission
Current context of pharmaceutical production in the EU and major challengesSRC
26 Mar 2026
Nils Behrndt
Deputy Secretary-General
Current context of pharmaceutical production in the EU and major challenges
26 Mar 2026
Nils Behrndt
Deputy Secretary-General
Current context of pharmaceutical production in the EU and major challengesSRC
25 Mar 2026
Stéphane Séjourné
Executive Vice-President
International context of the pharmaceutical industrySRC
25 Mar 2026
Estelle Goeger
Cabinet member
International context of the pharmaceutical industry
25 Mar 2026
Estelle Goeger
Cabinet member
International context of the pharmaceutical industrySRC
25 Mar 2026
Anna Nykiel-mateo (Cabinet member),Estelle Goeger (Cabinet member),Stéphane Séjourné (Executive Vice-President)
Cabinet of Executive Vice-President Stéphane Séjourné
International context of the pharmaceutical industrySRC
25 Mar 2026
Stéphane Séjourné
Executive Vice-President
International context of the pharmaceutical industry
19 Mar 2026
Marc Lemaitre
Director-General
Next generation of European public-private partnerships under FP10 / Horizon Europe
19 Mar 2026
Marc Lemaître (Director-General)
Commission
Next generation of European public-private partnerships under FP10 / Horizon EuropeSRC
19 Mar 2026
Marc Lemaitre
Director-General
Next generation of European public-private partnerships under FP10 / Horizon EuropeSRC
25 Feb 2026
Unknown
Commission
Exchange of views on EU cooperation with China and Japan inSRC
25 Feb 2026
Lucian Cernat
Head of Unit
Mutual Recognition Agreements (MRAs) for pharmaceutical products with reference to the UK and TürkiyeSRC
25 Feb 2026
Lucian Cernat
Head of Unit
Mutual Recognition Agreements (MRAs) for pharmaceutical products with reference to the UK and Türkiye
25 Feb 2026
Lucian Cernat (Head of Unit)
Commission
Mutual Recognition Agreements (MRAs) for pharmaceutical products with reference to the UK and TürkiyeSRC
25 Feb 2026
Marco Chirullo
Head of Unit
Exchange of views on EU cooperation with China and Japan in the field of biopharmaceutical innovation and supply chain resilience.
25 Feb 2026
Marco Chirullo
Head of Unit
Exchange of views on EU cooperation with China and Japan in the field of biopharmaceutical innovation and supply chain resilience.SRC
17 Feb 2026
Olivér Várhelyi (Commissioner)
Cabinet of Commissioner Olivér Várhelyi
Biotech Act, Pharma package, CMASRC
17 Feb 2026
Olivér Várhelyi
Commissioner
Biotech Act, Pharma package, CMA
17 Feb 2026
Olivér Várhelyi
Commissioner
Biotech Act, Pharma package, CMASRC
11 Feb 2026
Maya Matthews (Head of Unit)
Commission
Exchange of views on operations under the HTA Regulation with a focus on joint clinical assessments (JCAs)SRC
11 Feb 2026
Jana Dabbelt (Cabinet member)
Cabinet of Commissioner Olivér Várhelyi
Environmental legislationSRC
11 Feb 2026
Jana Dabbelt
Cabinet member
Environmental legislationSRC
11 Feb 2026
Jana Dabbelt
Cabinet member
Environmental legislation
11 Feb 2026
Maya Matthews
Head of Unit
Exchange of views on operations under the HTA Regulation with a focus on joint clinical assessments (JCAs)SRC

Mission & Goals

EFPIA represents the biopharmaceutical industry operating in Europe. Through its direct membership of 37 national associations, 38 leading pharmaceutical companies, and a growing number of small and medium-sized enterprises (SMEs), EFPIA’s mission is to create a collaborative environment that enables our members to innovate, discover, develop and deliver new therapies and vaccines for people across Europe, as well as contribute to the European economy. Our vision is for a healthier future for Europe. A future based on prevention, innovation, access to new treatments and better outcomes for patients. EFPIA’s activities extend to all matters of common interest to its members. In particular, it aims to foster an environment that encourages pharmaceutical research and development, manufacture in compliance with high-quality standards, intellectual property protection and the introduction of regulatory requirements to allow patients rapid access to medicinal products.

EU Legislative Interests

Any health or pharmaceutical policy stemming from the European institutions, such as - but not exclusive - Industrial Policy, Pharmaceutical Strategy, pharmaceutical, orphan and paediatrics legislation, Horizon Europe Research Programme, HTA policy, IP policy, One Health Approach to tackle AMR, COVID-19 outbreak measures. EFPIA also follows ongoing trade negotiations and legislative files relevant to the innovative pharmaceutical industry (such as Green Deal, Water Framework Directive, Welfare of animals in scientific testing etc). Main EU legislative proposals or policies targeted (a non-exhaustive list) A Pharmaceutical Strategy for Europe – over 50 legislative and non-legislative proposals • Directive 2001/83/EC on the Community code relating to medicinal products for human use • Regulation (EC) No 726/2004 of the European Parliament and of the Council laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency • Regulation (EC) No 141/2000 of the European Parliament and of the Council on orphan medicinal products. • Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for paediatric use In addition, we also follow for example: • Clinical Trial Regulation • EMA Fees Regulation • Europe’s Beating Cancer Plan • European Health Data Space • HERA Regulation • SPCs Regulation revision

Communication Activities

EFPIA communications activities include: • Publishing new evidence (etc. reports, leaflets, infographics) on the policies mentioned above on efpia.eu • Drafting blog post to share opinions • Organising events including EFPIA members and external stakeholders • Disseminating our key messages through media and social media

Interests Represented

Promotes their own interests or the collective interests of their members

Member Of

BIAC British Chamber of Commerce DIA EACD EAPM ECPA EPAA - European Partnership for Alternative Approaches to Animal EPC FAIB FEAM - Federation of European Academies of Medicine Friends of Europe Kangaroo Group Patients Access Partnership TOPRA THE EUROPEAN HOUSE – AMBROSETTI

Organisation Members

EFPIA’s constituent entities include: • 38 corporate members (companies) • 37 member associations (national associations) • 16 SMEs • 31 Partners in Research http://www.efpia.eu/about-us/membership

Additional Information

According to our calculations, the declared above amount as per guidelines, is correct. The estimate of annual costs related to activities covered by the register covers personnel related expenses as well as the costs related to intermediary activities.

Connected Legislation